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and the role of the catecholaminegic system in the action of 
these compounds.
For the purposes of this experiment, the effects of Di-
umancol and Decurcinol on behavior were studied on the basis 
of the pharmacological analyzer α-methyl tyrosine, whose 
effect on catecholamine metabolism and clonidin is such that 
it changes the function of presynaptic α-adrenergic receptors. 
In an attempt to elucidate if a change in NA (noradrenalin) 
and DA (dopamine) levels were involved in the central ac-
tion of Diumancol and Decurcinol, as reported in various 
preclinical studies, monoamines concentrations in three brain 
structures (striatum, frontal cortex and hypothalamus) were 
quantified.
Materials and methods
The experiments were performed on 144 male adult 
rats, in two stages:
Ist stage – neuropharmacological studies
IInd stage – neurochemical studies
 During the first stage of the evaluation of complex 
behavioral activity in the animals, the method of “open field” 
was used. Behavioral reactions—horizontal (the count of 
passed squares), vertical (the count of standing on hind legs), 
searching (looking into the holes), grooming (the count of rub-
bing down and cleaning actions) and defecation (the count of 
balls) ─ were observed in the course of 3 minutes. Behavioral 
reactions were observed 30 minutes after administration, i.e. 
when the investigated drugs reach their maximal concentra-
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Acţiunea Diumancalului şi a Decursinolului asupra sistemelor monoaminergice encefalice la şobolan
În experimente pe şobolani masculi a fost studiată acţiunea preparatelor Diumancal şi Decursinol – noi antagonişti de calciu – asupra 
comportamentului în zona receptorilor noradrenergici presinaptici α2, stimulaţi de clonidină şi prin epuizarea resurselor de noradrenalină şi 
dopamină de către alfa-metil tirozină. Diumancalul şi Decursinolul în doze mici reduc hipoactivitatea indusă de clonidină, pe când în doze 
mari nu potenţează semnificativ sedaţia indusă de clonidină. Uzul combinat al preparatelor nominalizate cu alfa-metil tirozină nu influenţează 
semnificativ reacţiile de comportament. Rezultatele obţinute sugerează despre rolul autoreglării presinaptice şi al modificării nivelului de 
neurotransmiţători în mecanismul de acţiune al preparatelor Diumancal şi Decursinol care pot fi utilizate în tratamentul dereglărilor de 
comportament la unii bolnavi psihici. 
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Действие диуманкала и декурсинола на моноаминергические системы мозга крысы
В опытах на белых крысах (самцых) было изучено влияние новых блокаторов кальциевых каналов – диуманкала и декурсинола на 
поведенческие реакции на фоне активации пресинаптических норадренергических α2 – рецепторов клонидином и на фоне истощения 
лабильных депо норадреналина и дофамина альфа метил тирозином. Было установлено, что оба препарата в малых дозах частично 
устраняют угнетение поведенческих реакций, вызванных клонидином, а в больших дозах потенцируют угнетение. Комбинированное 
применение малых доз соответствующих препаратов с α-метил тирозином не выявило изменений поведенческих реакций. Полученные 
данные дают возможность предположить существование пресинаптической ауторегуляции и лабильного депо нейротрансмиттеров как 
механизмы действия диуманкала и декурсинола, что может быть использовано в лечении некоторых психических заболеваний.
Ключевые слова: поведенческие реакции, норадренергическая система, диуманкал, декурсинол.
Introduction
Experimental and clinical investigations show that 
calcium-channel blockers (CCB) have marked psychotropic 
properties. The profile of their central activity is unique and 
spans a wide range of effects [4].
In comparison with well-known phenylalkylamin and 
1,4-dihydropyridine derivatives, putative new generation cal-
cium antagonists like 2H 1 benzopyrane 2-on derivatives–di-
umancol and decurcinol are more sensitive to N and T- type 
voltage-dependent calcium channel proteins [7]. Taking into 
account the effect of N-type channels as modulation of Ca-
depending release of neurotransmitters from the presynaptic 
membrane, the investigation of presynaptic mechanisms of 
2H1 benzopyrane 2-on derivative-CCBs like Diumancal and 
Decurcinol are a great scientific interest [3]. 
Diumancal (whose chemical structure is; 7,7-ethyl-
endioxy 2 H benzopyrane 2,2 dyon) is used with success in 
cardiologic practice as an anti-anginal, anti-ischemic and 
anti-arrhythmic drug. Other investigated the calcium-channel 
blocker Decurcinol (2,2-dimehtyl-3-oxy-3,-4-dyhidropy-
rano5,6: 6, 7-coumarin), extracted from the roots of Ceceli 
Grandvittatum, which is endemic to the region and demon-
strates markedly anti-arrhythmic effects. Existing evidence 
claims that Diumancol and Decurcinol have psychopharma-
cological profiles of action [5].
In view of potential psychotropic activity, the main 
purpose of the present study is the analysis of the effects of 
Diumancal and Decurcinol on neuro-mediator processes, 
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tion in CNS. Effective experimental dosages of medications 
were taken from literature. 
Isotonic saline solution and α-methyl tyrosine (200mg/
kg) were injected intraperitoneally into the control group 
and 2nd group of animals, accordingly. α-methyl tyrosine is 
an inhibitor of tyrosinhydroxilase, which converts tyrosin to 
DOPA (dihydroxyphenylalanine). It reduces or exhausts the 
endogen resources of mediators, depending on the size of the 
dose. The dose that we used of α-methyl tyrosine, caused the 
reduction of dopamine and norepinefrin levels in the CNS 
(25-35% and 40-50%, accordingly) 5 hours after administra-
tion [6]. Taking this fact into account, 4 hours and 30 minutes 
after the administration of α-methyl tyrosine, Diumancal 
(0,1mg/kg) and Decurcinol (1mg/kg) were injected into 
the 3rd group of animals and after 30 minutes their behavior 
reactions was observed in the duration of 3 minutes. The 4th 
group of animals was intraperitoneally administrated clonidin 
(0,05mg/kg). The 5th group of animals received 0,1; 1 mg/kg 
Diumancal and 1; 10mg/kg Decurcinol on the background of 
clonidin, and their behavior was observed within the course 
of 3 minutes, 30 minutes after admission. 
Diumancal, Decurcinol and α-methyl tyrosine were 
prepared ex tempore as a suspension in isotonic saline solution 
by the addition of Twin-80 in a 200mg/kg dosage. Clonidin 
was prepared as a suspension in isotonic saline solution in a 
0,05mg/kg dosage and administered intraperitoneally. 
All chemicals used were of the highest quality avail-
able.
During the second stage of experimented, conducted 
on a basis of Diumancal and Decurcinol pretreatment, NA 
and DA levels were detected in 3 structures of the rat’s brain 
when compared with control animals. 
For the measurement of NA and DA in brain tissue, the 
single-step method offered by B.M. Kogan and N.V. Nechaev 
was used [8]. In order to avoid the effects of circadian rhythms 
to neurotransmitter levels, rats were decapitated at 09:00 a.m. 
in the laboratory ward, where a temperature of 22°C was 
maintained. DA fluorescence was measured at a 330 nm ex-
citation wave and 420 nm fluorescence. NA fluorescence was 
accordingly measured at a 380 nm excitation wave and 478 
nm fluorescence. The intensity of DA and NA fluorescence 
was calculated on the basis of the difference between ex-
amination and control tests. The Intensity of fluorophors was 
analyzed with the “HITACHI”-MDF-4 spectrofluorometer. 
Statistical analysis was performed according to the Wil-
coxon-Mann-Whitney nonparametric method and on MC 
EXCELL XP and C-PLUS 2000 computer programs.
Results and Discussions
Initial investigations showed that low doses of diuman-
cal and decurcinol increases the activity of horizontal, verti-
cal and searching reactions, without significant changes in 
motor activity, and doesn’t cause any statistically significant 
changes in grooming and defecation functions. High doses 
of investigated calcium antagonists reduce all types of motor 
activity and cause sedation. These results correspond with 
the results of other investigators, regarding the reduction of 
behavioral reactions by calcium antagonists, and confirm the 
information that Diumancal potentiates the effects of other 
CNS depressants [9]. The dose-dependent central effects of 
both medications could be related to the roles of different 
neuro-mediator systems in the mechanism of action of these 
medications. In order to find out the relation of stimulating 
effects of low doses of Diumancal and Decurcinol to catechol-
aminergic systems, these substances are investigated against 
the background of α-methyl tyrosine.
As is shown in Table 1, low doses of Diumancal and 
Decurcinol were completely ineffective in preventing sedative 
effect of α-methyl tyrosine.
Table 1
Behavioral Reactions Observed During the Combination  
of Diumancal and Decurcinol with α-methyl tyrosine
Substances Horizontalactivity
Vertical
activity
Searching
activity
Groom-
ing
Defeca-
tion
Control 19,9  (17-22)
2,3 
(1-3)
3,1  
(2-4) 5,6 (4-7) 1,0 (0-2)
α-МТ  
200 mg\kg
9,9 
 (8-12)
1,4 
 (0-3)
1,6  
(1-2) 2,8 (2-4) 0,9 (0-2)
αМТ+ 
diumancal  
0,1 mg\kg
10,1 
 (9-12)
1,5  
(1-2)
1,4  
(1-2) 2,1 (1-3) 0,5 (0-1)
αМТ+ 
decurcinol 
1 mg\kg
10,4  
(9-12)
1,6  
(1-2)
1,5  
(1-2) 2,0 (1-3) 0,9 (0-1)
Note: 1- Control-normal isotonic solution, α-MT - α-methyl 
tyrosine. 2 - Statistical significance according to Wilcoxon-
Mann-Whitney: p < 0,05
Taking into consideration that α-methyl tyrosine has 
tropism to labile storages of monoamines, it is concluded 
that labile depots of neurotransmitters play a role in fact that 
Diumancal and Decurcinol stimulates behavioral reactions in 
low doses, but doesn’t alter this activity when used in combi-
nation. On the other hand, the possible modulating effect on 
presynaptic auto-regulative mechanisms (because of sensitiv-
ity to N- and T- type calcium channels) may have a role in the 
stimulating effect of these medications in low doses.
In order to define in detail the role of presynaptic 
auto-regulative adrenergic mechanisms in the mechanism of 
action of diumancal and decursinol, both medications were 
investigated against the background of clonidin.
It is known that clonidin decreases locomotor activ-
ity and other behavioral reactions, which is explained by its 
stimulating effect on presynaptic α2 adrenergic receptors and 
its slowing down of the release of noradrenalin.
Diumancal, administered in doses of 0,1mg/kg, slightly 
reduced the clonidine-induced hypo activity and sedation 
in the rats. This effect was more remarkable in horizontal 
and vertical reactions. Low doses of diumancal restored the 
activity of horizontal and vertical reactions in 1,3 (p<0,005) 
and 1,5(p<0,05) times accordingly. There were not any sta-
tistically significant changes in defecation, grooming and 
searching components of behavioral reaction. Despite the 
fact that lower doses of diumancal were able to antagonize 
clonidine-induced behavioral inhibition, these indicators were 
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lower than in control animals injected with normal saline 
solution (Fig.1).
Decurcinol, administered in a 1mg/kg dose, caused a 
similar effect to Diumancal administered in a 0.1mg/kg dose, 
but its effect was weak. Antagonism to clonidin low doses of 
2H1-benzopyrane 2-on derivatives, may be attributed to the 
blockade of presynaptic alpha -2-receptors (autoreceptors). 
These facts confirm the information published in medical 
literature that claims that some calcium channel blockers 
blockade presynaptic α2 adrenergic receptors [1].
On the other hand, the evident stimulating effect of 
Diumancal and Decurcinol on the background of blockade 
of presynaptic α2 adrenergic receptors by clonidin, provides 
enough of a basis to conclude that other mediator systems 
have a role in the mechanism of action of these medications, 
as well. 
The behavioral activity of animals receiving low doses 
of Diumancal and Decurcinol was completely different from 
the locomotor activity of animals that received high doses of 
both medications with the combination of clonidin. In both 
cases, high doses deepen the sedative effect produced by 
clonidin. Despite the fact that this effect was not statistically 
clear, the result shows that 2H1-benzopyrane 2-on derivatives 
influence to CNS is very complicated, and there is a need 
for broad neuro-pharmacological and even neuro-chemical 
investigation. 
The evidence that CCB-s open these structures in low 
doses and block in high doses, and besides this, the fact that 
clonidin blocks N-type calcium channels, explains why di-
umancal and decurcinol in high doses potentiates the sedative 
effect of clonidin [2].
In the second stage of present study, the regional concen-
tration of NA and DA were measured on the hypothalamus, 
striatum and the frontal cortex of rats. The results once again 
confirmed that CCB’s have unique neuro-chemical action. As 
shown in Table 2, diumancal in a 0,1mg/kg dose decreased 
the levels of NA in the hypothalamus and frontal cortex, but 
increased its levels in striatum in 7,6%. Low doses of diuman-
cal increased the levels of DA in the hypothalamus and the 
frontal cortex in 10,2% and 10,5% accordingly, but decreased 
its levels in striatum by 9%.
The results of the neuro-chemical investigation of De-
curcinol (1mg\kg) were different from those of the Diumancal 
in a 0,1mg\kg dose. A 1mg\kg dose of Decurcinol significantly 
decreased NA levels in the hypothalamus and frontal cortex, 
Table 2
The Effect of Diumancal, Decurcinol and Verapamil on Levels of Monoamines (ng/g) in Rat’s Brains
Substance Dose mg\kg
Hypothalamus Striatum Frontal cortex
NA DA NA DA NA DA
Control NaCl 0,9% 689,6 (675-700) 756,6 (740-770) 563,8 (546-580) 642,1 (620-668) 548,1 (520-574) 582,0 (565-590)
Diumancal 0,1 617.8* (605 625) 774.4** (750-790) 606.8* (590-620) 584.3 ** (570-600) 493.6* (478-504) 612.8* (600-624)
Diumancal 1 527.3* (520-538) 683.9* (674-694) 401.6* (388-415) 553.6* (535-570) 416.0* (410-426) 468.6* (460-475)
Decurcinol 1 601.6* (580-625) 689.1* (674-700) 582.9* (546-610) 544.1* (535-550) 456.8* (448-475) 597.1** (510-616)
Decurcinol 10 581.8* (564-596) 613.4* (600-624) 469.5* (460-480) 464.5* (456-475) 445.1* (430-458) 469.0* (460-480)
Statistical significance according to Wilcoxon-Mann-Whitney: *p<0.001; **p<0.05
Fig. 1. The Influence of Diumancal to Motor Reactions against a Background of Clonidin.
Note: 1- control group of animal injected normal saline solution; 2- diumancal 0,1mg/kg; 3- clonidin 0,05mg/kg; 4- diumancal 
0,1mg/kg+clonidin0,05mg/kg. Statistical significance according to Wilcoxon-Mann-Whitney: horizontal activity p<0,005; vertical 
activity p <0,05; searching activity p >0,05; grooming p >0,05; defecation p <0,05.
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and increased the striatal NA level 2,2 times less than 0,1 
mg\kg Diumancal. Decurcinol (1 mg\kg), but not Diumancal, 
decreased hypothalamic DA. 
The stimulating effect of low doses of Diumancal, in 
comparison with Decurcinol, is related to the fact that Di-
umancal severely increases striatal NA and increases the DA 
level in the hypothalamus differently from decurcinol.
High doses of Diumancal (1mg/kg) and Decurcinol 
(10mg/kg) decrease the levels of NA and DA in all three brain 
structures. This fact is a possible explanation for the sedative 
effect of these medications.
In conclusion, the behavioral and biochemical changes 
produced by novel CCB-s Diumancal and Decurcinol could 
be of great interest in light of the possible use of calcium an-
tagonists to treat disorders of the central nervous system.
Conclusions
1. Diumancal and decurcinol were completely ineffec-
tive in preventing the sedative effect of α-methyl tyrosine.
2. Both medications, when administered in low doses, 
slightly reduced clonidine-induced sedation in rats. This ef-
fect was more remarkable in horizontal and vertical reactions. 
There were not any statistically significant changes in the 
defecation, grooming and searching components of behavioral 
reactions.
3. Both in high doses deepens clonidin induced seda-
tion, but not in a way that is statistically significant.
4. Diumancal and decurcinol both affect the brain bio-
genic amines, suggesting both the inhibition and activation 
of monoaminergic systems, according to dosage.
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Coma hepatică virală B şi/sau D la gravidele cu eclampsie nonconvulsivă
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The Hepatic Coma of Viral Origin B and/or D in Pregnancy and in Eclampsia without Convulsions
The hepatic coma of viral origin B and/or D occurs during all periods of pregnancy but is more common during the last trimester.  Pregnancy 
in the last trimester can be complicated by eclampsia characterized by specific clinical symptoms which evolve into coma.  Very few cases are 
known of a coma in pregnancy which evolved during eclampsia without convulsions. The diagnosis of these cases is difficult.  The article describes 
a coma which evolved during eclampsy without convulsions which was initially believed to be an hepatic coma of viral (B) etiology. 
Key words: hepatic viral coma, eclampsia.
Печеночная кома вирусной этиологии В и/или D у беременных с бессудорожной эклампсией 
Печеночная кома вирусной этиологии В и/или D не исключается во всех периодах беременности. Беременность в последнем 
триместре может осложняться эклампсией, протекающей с характерными клиническими симптомами и с развитием комы. Реже 
печеночная кома у беременных развивается при эклампсии, протекающей без судорог. В подобных случаях дифференциальная 
диагностика комы сложна. Описывается случай комы при эклампсии без судорог, первоначально принятая как печеночная кома 
вирусной В этиологии.
Ключевые слова: печеночная кома вирусной этиологии, эклампсия.
